John Kauh

John Kauh has extensive work experience in the field of clinical development and oncology. John is currently serving as the Chief Medical Officer at Tvardi Therapeutics since January 2023. Prior to this, they worked at HUTCHMED where they held the positions of Vice President Clinical Development from September 2020 to February 2023 and Executive Director, Clinical Development from September 2018 to September 2020. John also worked at Glenmark Pharmaceuticals as the Executive Director Clinical Sciences - Oncology from May 2017 to September 2018. Before that, they worked as a Sr. Medical Director at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company from November 2013 to May 2017. John started their career at Emory University School of Medicine as an Associate Professor of Hematology/Oncology from August 2003 to October 2013.

John Kauh started their education at Pennsylvania State University, where they obtained a Bachelor of Science (BS) degree in an unspecified field of study. John then went on to attend Thomas Jefferson University from 1993 to 1997, earning a Doctor of Medicine (MD) degree in Medicine. After completing their medical degree, John pursued further specialization in Hematology and Oncology through a fellowship at Georgetown University School of Medicine, from 2000 to 2003. Prior to their fellowship, they also completed an Internal Medicine Residency at Baylor College of Medicine between 1997 and 2000. In terms of additional certifications, John obtained certifications in Medical Oncology and Internal Medicine from the American Board of Internal Medicine in 2003 and 2000, respectively.